The company launched a "core" service using Illumina microarray genotyping, and has plans for an expanded NGS offering with Quest Diagnostics.
The companies will offer customers a way to mine 23andMe's customer base for subjects with specific genetic or clinical features, and design and conduct a trial around them.
As part of the shift, DNA.Land, which was run as an academic research project, will delete all data by the end of the month and ask customers to resubmit it.
The Cancer Journal documented 25 cases where inappropriate tests were ordered, variants were interpreted incorrectly, and wrong results were reported to patients.
While the FDA has expressed concerns about PGx testing, CEO Erik Hennings said the company has taken measures to limit the risk of consumer harm.
23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits.
In a pilot study, EMD Serono will have the genomes of lung cancer patients sequenced for research but participants will also gain access to their genomic data.
Several genetic test providers thought Helix would give them a national sales channel for their genomics apps, but this didn't materialize.
A company executive confirmed that Helix has laid off an undisclosed number of employees and is closing its Denver and San Francisco offices.
Illumina said that the DTC market is in "transition" from ancestry and genealogy to one driven by demand for health information.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.